BUDOPRUTUG
UNII E4ET672BAP

Substance Identification & Data

This profile provides standardized clinical and technical data for Budoprutug, uniquely identified by the FDA Unique Ingredient Identifier (UNII) E4ET672BAP.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2720478-38-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

E4ET672BAP

CAS Registry Number

2720478-38-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

BUDOPRUTUG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C203028

National Cancer Institute reference terminology for clinical and research data.

INN ID

12546

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Budoprutug. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

BUDOPRUTUG

Common Names & Synonyms

BUDOPRUTUG [INN]

BUDOPRUTUG [WHO-DD]

GAMMA1 HEAVY CHAIN (1-450) (VH MUSMUS/HOMSAP (MUS MUSCULUS IGHV1-69*02(85.7%) -(IGHD) -IGHJ4*01(100%)/HOMO SAPIENS IGHV1-46*01 (67.3%) -(IGHD) - IGHJ4*01 (92.3%) L123>S (115), CDR-IMGT (8.8.13) (26-33.51-58.97-109)) (1-120) -HOMO SAPIENS IGHG1*03 (100%), G1M3, NG1M1 CH1 R120, E12, M14 (CH1 R120 (217) (121-218), HINGE 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)), (223-211')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-211') (V-KAPPA MUSMUS/HOMSAP (MUS MUSCULUS IGKV4-70*01 (90.3%) - IGKJ1*01 (100%)/HOMO SAPIENS IGKV3D-11*01 (63.8%) - IGKJ4*01 (90.9%) V124>L (101'), CDR-IMGT (5.3.7) (27'-31'.49'-51'.88'-94')) (1'-104') -HOMO SAPIENS IGKC*01 (100%), KM3, A45.1 (150'), V101 (188') (105'-211')); DIMER (229-229'':232-232'')-BISDISULFIDE, PRODUCED IN YB2/0 CELL LINE, GLYCOFORM ALFA

IMMUNOGLOBULIN G1 (DE-450-LYSINE), ANTI-(HUMAN CD19 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL VB119 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL VB119 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD19 (B LYMPHOCYTE SURFACE ANTIGEN B4, LEU-12)), MONOCLONAL ANTIBODY